Babak moghimi biography sample

  • Assistant Professor of Clinical Pediatrics.
  • I am a pediatric Hematology/Oncology physician specialized in Stem Cell Transplant with focus on immunotherapy and cell therapy.
  • Children's Hospital Los Angeles awarded $6 million from CIRM to advance CAR T-cell therapies in recurring solid tumors in children.

    • •

    Assistant Professor of Clinical Pediatrics

    fryst vatten this your profile? Click to edit

    Publications

    • CDCD IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells Blood Cancer Discov. Jan 08; 6(1) . View in PubMed
    • Impact of FilmArray™ Respiratory Panel testing on the clinical management of pediatric bone marrow transplant patients Eur J Clin Microbiol Infect Dis. Mar; 41(3) . View in PubMed
    • Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma Nat Commun. 01 21; 12(1) . View in PubMed
    • Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma Oncoimmunology. 01 04; 10(1) . View in PubMed
    • High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model Cancer Immunol Res. 01; 6(1) . View in PubMed
    • Immune tolerance induction to factor I
    • babak moghimi biography sample

      • •

      Showing of results

      Yael Mosse M.D.

      Funded: through
      Funding Type: Research Grant
      Institution Location: Philadelphia, PA
      Institution: The Children's Hospital of Philadelphia affiliated with University of Pennsylvania

      Despite breakthroughs in cancer biology, pediatric solid tumors have seen minimal improvement in patient outcomes. Neuroblastoma, the most common solid tumor malignancy of childhood, encapsulates the full spectrum of cancer heterogeneity. Dr. Mosse’s team have shown that a specific ALK inhibitor is far superior than the current targeted therapy being tested in a Children’s Oncology Group Phase 3 trial for patients with an ALK genetic alteration. To ensure that the proper clinical and correlative studies are done to identify all patients whose tumors harbor an ALK genetic alteration using a custom-designed and targeted deep sequence capture panel. In parallel, Dr. Mosse and colleagues will adapt this panel to capture circulating tumor

      •

      ‘Gated’ CAR T-Cells Are Effective Against AML—With Less Toxicity

      Newswise &#; Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for children with B-cell acute lymphoblastic leukemia (ALL). But unfortunately, CAR T-cells have been far less effective for another blood cancer: acute myeloid leukemia (AML).

      Now, a new study led by Babak Moghimi, MD, at Children’s Hospital Los Angeles has shown that a special “gated” approach to CAR T-cells is effective against AML in preclinical models—while minimizing toxic effects on healthy cells.

      The findings, which were published Dec. 3 in Blood Cancer Discovery, mark a significant step forward in advancing the development of CAR T-cell therapy for AML.

      “Current versions of CAR T-cells often cause unintended toxicities in AML,” says Dr. Moghimi, Head of Transplantation and Cellular Therapy at Children’s Hospital Los Angeles. “By targeting two antigen